Tier 2 — strong

An Application of a Large-Scale, Data-Driven Approach to Prioritize Compound-Targeted Conditions in the Nutraceutical Space: Case Study of QuercefitTM (Quercetin Phytosome) Toward Unbalanced Lipid Conditions in Metabolically Challenged Adults

Loukia Lili, Sheena Smith, Laura Kunces, Riva Antonella, Pietro Allegrini, Stefano Togni, Serena Tongiani, Nate Rickard, Benjamin Readhead, Stephen Phipps, Bodi Zhang
Molecular nutrition & food research 2025 69(22):e70253

Bibliography

PubMed
PMID 40936357
PubMed Central
PMC12643186
DOI
10.1002/mnfr.70253
Funding
Indexed grant support: Indena SpA and Thorne HealthTech, Inc. The indexed list may not contain the complete funding declaration.
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignComputational target-prioritization study with human proof-of-concept component
ModelMixed human intervention and laboratory research
SampleMetabolically challenged adults; clinical sample size not stated in the indexed abstract
InterventionQuercefit quercetin-phytosome formulation; dose not stated in the abstract
DurationClinical schedule not stated in the indexed abstract
EndpointsLipid measurements

What the study showed, in plain terms

Published in 2025, this source examined cardiovascular and metabolic health. Design: Computational target-prioritization study with human proof-of-concept component. Sample/model: Metabolically challenged adults; clinical sample size not stated in the indexed abstract. The exposure or intervention was Quercefit quercetin-phytosome formulation; dose not stated in the abstract. Follow-up or treatment period: Clinical schedule not stated in the indexed abstract.

The authors report favorable lipid findings following a computational hypercholesterolemia prediction.

The abstract does not provide sufficient clinical methods or effect estimates for a firm efficacy conclusion. Computational disease links are not independent clinical validation.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The authors report favorable lipid findings following a computational hypercholesterolemia prediction.
  • The recorded outcome domains were Lipid measurements.
  • The result applies to the tested exposure: Quercefit quercetin-phytosome formulation; dose not stated in the abstract; Clinical schedule not stated in the indexed abstract.

What this study can and cannot tell us

  • The abstract does not provide sufficient clinical methods or effect estimates for a firm efficacy conclusion. Computational disease links are not independent clinical validation.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology